Hepatitis C Enrollment Form



Fax Referral To: 1-855-297-1270

Phone: 1-888-280-1190 Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927 NCPDP: 4026325

DATIENT INCOME		o Submitting a Referral				
	'ION (Complete or include demograpi					
			er: 🔲 Male 🔛 Female			
Address:		City, State, ZIP Code:)	acil (to appoil provide d balave)			
		and email address above, you are consenti				
		iption(s), account, and health care. Standar macy will attempt to contact by phone.	a data rates apply. Message			
imail:	L oot Ec	Alternate Phone: our of SSN: Primary Language:				
		Relationship to patient:				
PRESCRIBER INFOR		Relationship to patient.				
		01-1-12				
rescriber's Name:	State License #: State License State Sta					
IPI #: DEA #: _	Group or Hospital:	City State 7ID Code:				
Phone:	Fay Contact P	City, State, ZIP Code: Contactions:	ct's Phone:			
_						
INSURANCE INFORM	MATION Please fax copy of prescription	on and insurance cards with this form, if avail	able (front and back)			
DIAGNOSIS AND CI	INICAL INFORMATION					
		Office Other:				
viagnosis (ICD-10):	Ship to Patient	Onice Couler.				
B17.10 Acute Hepatitis C w	rithout hepatic coma ☐ R17 11 ∆cı	ute Hepatitis C with hepatic coma				
B18.2 Chronic Hepatitis C		nspecified Viral Hepatitis C without hepatic	coma			
B20 HIV		de: Description				
atient Clinical Information:						
illergies:		ight:lb/kg	n			
		No Cirrhosis Compensated Cirrhosis	Decomposed Cirrhosis			
1CV Genotybe: i ila i ilb i	11 1 12 1 13 1 14 1 15 1 16 AND 1 1	NO CITTIOSIS I I COMPENSALEA CITTIOSIS	i i becombensated cirriosis			
s patient: 🗍 Naïve 🔲 Partial	Responder Non-Responder Rela	apser; Last Date of Therapy: Prod	uct Name(s):			
s patient: Naïve Partial s patient currently on Hepatit	Responder \[\] Non-Responder \[\] Relations Relations \[\] No \[\] Yes, Ther	apser; Last Date of Therapy: Prod apy Start Date: Product Nam	uct Name(s): e(s):			
s patient: \(\bar{\text{Naive}} \) Partial s patient currently on Hepatit s patient post-liver transplant	Responder Non-Responder Relais C Virus therapy? No Yes, There? No For Zepatier	apser; Last Date of Therapy: Prod	uct Name(s): e(s):			
s patient: \(\bigcap \)Naïve \(\bigcap \)Partial patient currently on Hepatits patient post-liver transplant \(\bigcap \)PRESCRIPTION INFO	Responder Non-Responder Relais C Virus therapy? No Yes, Therapy? Sor Zepatier	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism	uct Name(s): e(s): n present? Yes No			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION	Responder Non-Responder Relais C Virus therapy? No Yes, There? No For Zepatier	apser; Last Date of Therapy: Prod apy Start Date: Product Nam	uct Name(s):e(s): n present? Yes No			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION	Responder Non-Responder Relatis C Virus therapy? No Yes, Therative Por Zepatier ORMATION STRENGTH	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism	uct Name(s): e(s): n present? Yes No QUANTITY/REFILLS Quantity:			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION Epclusa Tablet (sofosbuvir and	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier CORMATION STRENGTH Fixed-dose combination tablet of	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS	uct Name(s):e(s): n present? Yes No			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION DEPCLUSA Tablet (sofosbuvir and	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier CORMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism	uct Name(s): e(s): n present? Yes No QUANTITY/REFILLS Quantity:			
s patient: \(\bar{\text{Naive}}\) Partial s patient currently on Hepatits patient post-liver transplant \(\begin{align*} \text{PRESCRIPTION INF()} \\ \end{align*}	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier CORMATION STRENGTH Fixed-dose combination tablet of	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS	uct Name(s): e(s): n present? Yes No QUANTITY/REFILLS Quantity:			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION Epclusa Tablet (sofosbuvir and	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier CORMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily.	uct Name(s): e(s): n present? Yes No QUANTITY/REFILLS Quantity:			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION Epclusa Tablet (sofosbuvir and	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier CORMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle)	uct Name(s): e(s): n present? Yes No QUANTITY/REFILLS Quantity: Refills:			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION Epclusa Tablet (sofosbuvir and velpatasvir)	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier ORMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle)	uct Name(s): e(s): n present? Yes No QUANTITY/REFILLS Quantity:			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets	Responder Non-Responder Relatis C Virus therapy? No Yes, Therefore? Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets	QUANTITY/REFILLS Quantity: Refills: Quantity: 28-day supply Refills:			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier ORMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily	QUANTITY/REFILLS Quantity: Refills: Quantity: 28-day supply Refills: 12 weeks			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier ORMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of Unit-dose pellet packets of Unit-dose pellet packets of	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Pour packet(s) of oral pellets	QUANTITY/REFILLS Quantity: Refills: Quantity: 28-day supply Refills:			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION DEPOLUSA TABLET (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier ORMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Pour packet(s) of oral pellets directly into the mouth and swallow	QUANTITY/REFILLS Quantity: Refills: Quantity: 28-day supply Refills: 12 weeks			
s patient: Naïve Partial spatient currently on Hepatit spatient post-liver transplant PRESCRIPTION INFOMEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and	Responder Non-Responder Relations C Virus therapy? No Yes, There? Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Pour packet(s) of oral pellets directly into the mouth and swallow once daily	QUANTITY/REFILLS Quantity: Refills: Quantity: 28-day supply Refills: 12 weeks			
s patient: Naïve Partial spatient currently on Hepatit spatient post-liver transplant PRESCRIPTION INFOMEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and	Responder Non-Responder Relations C Virus therapy? No Yes, There? Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Pour packet(s) of oral pellets directly into the mouth and swallow	QUANTITY/REFILLS Quantity: Refills: Quantity: 28-day supply Refills: 12 weeks Other:			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and	Responder Non-Responder Relation C Virus therapy? No Yes, Thereform Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Pour packet(s) of oral pellets directly into the mouth and swallow once daily Other:	QUANTITY/REFILLS Quantity: Quantity: 28-day supply Refills: 12 weeks Other: Quantity: 28-day supply			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFO MEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and	Responder Non-Responder Relation C Virus therapy? No Yes, Thereform Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir Fixed-dose combination tablet of	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle)	QUANTITY/REFILLS Quantity: Quantity: 28-day supply Refills: 12 weeks Other: Quantity: 28-day supply Refills:			
spatient: Naïve Partial spatient currently on Hepatit spatient post-liver transplant PRESCRIPTION INFOMEDICATION BEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and velpatasvir) Harvoni	Responder Non-Responder Relation C Virus therapy? No Yes, Thereform Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg	apser; Last Date of Therapy: Prod apy Start Date: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Pour packet(s) of oral pellets directly into the mouth and swallow once daily Other: Take PO once daily with or without food. Do not take within 4 hours of	QUANTITY/REFILLS Quantity: Quantity: 28-day supply Refills: 12 weeks Other: Quantity: 28-day supply Refills: 8 weeks			
spatient: Naïve Partial patient currently on Hepatitic patient post-liver transplant patient patient post-liver transplant patient patie	Responder Non-Responder Relation C Virus therapy? No Yes, Thereform Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir Fixed-dose combination tablet of	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle)	QUANTITY/REFILLS Quantity: Quantity: 28-day supply Refills: 12 weeks Other: Quantity: 28-day supply Refills: 12 weeks 12 weeks 12 weeks 13 weeks 14 weeks			
spatient: Naïve Partial spatient currently on Hepatitis patient post-liver transplant patient pati	Responder Non-Responder Relation C Virus therapy? No Yes, Thereform Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg sofosbuvir	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Pour packet(s) of oral pellets directly into the mouth and swallow once daily Other: Take PO once daily with or without food. Do not take within 4 hours of antacids.	QUANTITY/REFILLS Quantity: Quantity: 28-day supply Refills: 12 weeks Other: Quantity: 28-day supply Refills: 24 weeks 24 weeks			
spatient: Naïve Partial spatient currently on Hepatitis patient post-liver transplant PRESCRIPTION INFOMEDICATION BEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and velpatasvir) Harvoni (ledipasvir and sofosbuvir)	Responder Non-Responder Relation C Virus therapy? No Yes, Thereform Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg sofosbuvir	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Pour packet(s) of oral pellets directly into the mouth and swallow once daily Other: Take PO once daily with or without food. Do not take within 4 hours of antacids.	QUANTITY/REFILLS Quantity: Quantity: 28-day supply Refills: 12 weeks Other: Quantity: 28-day supply Refills: 24 weeks 24 weeks			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant PRESCRIPTION INFOMEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and velpatasvir) Harvoni (ledipasvir and sofosbuvir)	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg sofosbuvir	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle)	QUANTITY/REFILLS Quantity: Refills: Quantity: 28-day supply Refills: Quantity: 28-day supply Refills: Quantity: 28-day supply Refills: 12 weeks Quantity: 28-day supply Refills: All Weeks 24 weeks de kits provided as needed for administration			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant patient post-liver transplant PRESCRIPTION INFOMEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and velpatasvir) Harvoni (ledipasvir and sofosbuvir) Patient is interested in patient support	Responder Non-Responder Relation C Virus therapy? No Yes, Thereform Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg sofosbuvir programs STAMP SIGNATURE REQUIRE	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle)	QUANTITY/REFILLS Quantity: Quantity: 28-day supply Refills: 12 weeks Other: Quantity: 28-day supply Refills: Allowed Allowed			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant patient post-liver transplant PRESCRIPTION INFOMEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and velpatasvir) Harvoni (ledipasvir and sofosbuvir) Patient is interested in patient support	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier DRMATION STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg sofosbuvir	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Pour packet(s) of oral pellets directly into the mouth and swallow once daily Other: Take PO once daily with or without food. Do not take within 4 hours of antacids. RE NOT ALLOWED Ancillary supplies and the product Selection Permittion / May Substitute / Product Selection Permittion / May Substitute / Product Selection Permitting Ancillary supplies and the product Selection Permitting Ancillary Supplies Ancillary S	QUANTITY/REFILLS Quantity: Quantity: 28-day supply Refills: 12 weeks Other: Quantity: 28-day supply Refills: Allowed Allowed			
s patient: Naïve Partial s patient currently on Hepatit s patient post-liver transplant patient post-liver transplant PRESCRIPTION INFOMEDICATION Epclusa Tablet (sofosbuvir and velpatasvir) Epclusa Oral Pellets (sofosbuvir and velpatasvir) Harvoni (ledipasvir and sofosbuvir) Patient is interested in patient support	Responder Non-Responder Relation C Virus therapy? No Yes, Therefore Yes No For Zepatier Por Zepatier No STRENGTH Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir Unit-dose pellet packets of 200 mg sofosbuvir and 50 mg velpatasvir Unit-dose pellet packets of 150 mg sofosbuvir and 37.5 mg velpatasvir Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg sofosbuvir programs STAMP SIGNATURE REQUIRE Cally Necessary / Do Not Substitute / No Substitute	apser; Last Date of Therapy: Product Nam genotype 1a patients, NS5A polymorphism DOSE & DIRECTIONS Take one tablet once daily. kg / lb (please circle)	QUANTITY/REFILLS Quantity: Refills: Quantity: 28-day supply Refills: 12 weeks Other: Quantity: 28-day supply Refills: Alloweds ALLOWED)			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Hepatitis C Enrollment Form
Please Complete Patient and Prescriber Information

atient Name:	Patient D0	Patient DOB: Patient Phone:		
rescriber Name:		Pr	rescriber Phone:	
PRESCRIPTION INI	FORMATION			
MEDICATION	STRENGTH		DOSE & DIRECTIONS	QUANTITY/REFILLS
Mavyret Tablet Fixed-dose combination tablet of 100 mg glecaprevir and 40 mg pibrentasvir Fixed-dose combination tablet of 100 mg glecaprevir and 40 mg pibrentasvir		three tablets PO once a day with food.	Quantity: 28-day supply Refills: 8 weeks 12 weeks Other	
Mavyret Oral Pellets (glecaprevir and pibrentasvir)	Unit-dose pellet packets of 50 mg glecaprevir and 20 mg pibrentasvir	kg / lb (please circle) Mix packet(s) of oral pellets with a small amount of soft food and swallow once daily Other:		Quantity: 28-day supply Refills: 8 weeks 12 weeks Other
Ribavirin	200 mg tablets 200 mg capsules	Take tabs/caps PO q am and tabs/caps q pm for a total of mg daily with food.		Quantity: Refills:
Sovaldi (sofosbuvir)	400 mg tablets	Take one 400 mg tablet PO once a day.		Quantity: 28-day supply Refills:
Vosevi sofosbuvir, velpatasvir, and voxilaprevir)	Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir/100 mg voxilaprevir	Take one tablet PO once a day with food.		Quantity: 28-day supply Refills: 12 weeks Other
Zepatier [elbasvir and grazoprevir]	Zepatier (elbasvir/grazoprevir)	Take one tablet once daily with or without food.		Quantity: 28-day supply Refills: 12 weeks 16 weeks
	. •	ED (S	Ancillary supplies and kits FAMP SIGNATURE NOT ALLO May Substitute / Product Selection Permitted /	provided as needed for administratio
DAW / May Not Substitute	Date:		Substitution Permissible Prescriber's Signature:	Date:

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and sub mit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.